Efficacy News and Research

RSS

Study finds higher rate of switching from Byetta to Victoza in treatment of type 2 diabetes

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that although Amylin/Eli Lilly's Byetta currently commands a higher patient share than Novo Nordisk's Victoza, more patients were switched from Byetta to Victoza than vice versa (25.2 percent versus 2.8 percent) in the last quarter of 2010 among recently treated type 2 diabetes patients.

8 Jul 2011

Scientists discover way to separate neural wheat from the chaff

University of Florida scientists have discovered a way to separate the neural wheat from the chaff during the process of generating brain cells for potential patient therapies.

8 Jul 2011

Researchers identify cellular origin of malignant glioma

Using a mouse genetic system co-developed by researchers at the University of Oregon and Stanford University, a research team led by UO biologist Hui Zong has isolated the cellular origin for malignant glioma, a deadly human brain cancer.

8 Jul 2011

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

InterMune today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis.

8 Jul 2011

ThromboView gets positive results in study evaluating accuracy and safety

Drug and diagnostic company Agenix Limited (ASX: AGX), today announced the positive results of a study to evaluate the efficacy and accuracy

7 Jul 2011

Final Atlantis space trip may open new era of research into infectious diseases

On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.

7 Jul 2011

Eighteen scientists receive Damon Runyon Cancer Research Foundation awards

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 18 new Damon Runyon Fellows at its spring Fellowship Award Committee review.

7 Jul 2011

Freeze-dried gene therapy system safe and effective for treating brain cancer

Researchers at the Johns Hopkins University School of Medicine have developed a technique that delivers gene therapy into human brain cancer cells using nanoparticles that can be freeze-dried and stored for up to three months prior to use. The shelf-stable particles may obviate the need for virus-mediated gene therapy, which has been associated with safety concerns.

7 Jul 2011

Treating migraines with behavioral approaches can make financial sense

Treating chronic migraines with behavioral approaches - such as relaxation training, hypnosis and biofeedback - can make financial sense compared to prescription-drug treatment, especially after a year or more, a new study found.

6 Jul 2011

New biological insights into fat tissue

For better or worse, a popular class of anti-diabetic drugs does more than lower blood sugar. One known as rosiglitazone has been in the spotlight for its possible link to increased cardiovascular events, but it also seems to come with unexplained vascular benefits and an unwelcome tendency for weight gain.

6 Jul 2011

Antimicrobial copper surfaces reduce risk of acquiring hospital infection

Professor Bill Keevil, Head of the Microbiology Group and Director of the Environmental Healthcare Unit at the University of Southampton, has presented research into the mechanism by which copper exerts its antimicrobial effect on antibiotic-resistant organisms at the World Health Organization's first International Conference on Prevention and Infection Control.

2 Jul 2011

Novel drug delivery device can treat diabetes-related retinal damage

A team of engineers and scientists at the University of British Columbia has developed a device that can be implanted behind the eye for controlled and on-demand release of drugs to treat retinal damage caused by diabetes.

1 Jul 2011

Small molecule treatment holds promise for Usher syndrome

New treatment approach shall soon be ready for use in Usher syndrome patients / Publication in "Human Gene Therapy".

1 Jul 2011

Lantheus commences flurpiridaz F 18 PET MPI Phase 3 trial for detection of coronary artery disease

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of the first of two Phase 3 clinical trials to assess myocardial perfusion using Positron Emission Tomography (PET) imaging with flurpiridaz F 18 in patients with suspected or known coronary artery disease (CAD).

1 Jul 2011

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

30 Jun 2011

Positive final results from Medicago's H5N1 Avian Influenza VLP vaccine Phase II trial

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive final results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

30 Jun 2011

VIVUS submits avanafil NDA to FDA for treatment of erectile dysfunction

VIVUS, Inc. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction.

30 Jun 2011

MR-guided focused ultrasound effective for treating essential tremor

The last ten years have been challenging for Billy R. Williams of Fort Valley, Virginia. The former Pentagon employee, who survived the 9/11 terrorist attack, has suffered from essential tremor, a progressive and debilitating neurological disorder.

30 Jun 2011

Novartis reports NVA237 Phase III trial results against COPD

Sosei Group Corporation, announces that results reported today by Novartis from the pivotal Phase III GLOW2 clinical trial show that once-daily NVA237 50 mcg significantly improved lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) relative to placebo, with similar efficacy to open-label tiotropium.

30 Jun 2011

Almirall, Forest Labs submit aclidinium bromide NDA to FDA for treatment of COPD

Forest Laboratories, Inc. and Almirall, S.A. announced they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for aclidinium bromide, a long-acting inhaled antimuscarinic agent developed for the treatment of COPD.

30 Jun 2011